The Clinical Utility of the Genomic Prostate Score in Men with Very Low to Intermediate Risk Prostate Cancer.

We retrospectively investigated the genomic prostate score assay in clinical practice at an urban tertiary care academic center.

We reviewed all Genomic Prostate Score results acquired during a 3-year period. Changes in patient NCCN (National Comprehensive Cancer Network®) risk group, including very low, low, intermediate or high risk, and ultimate management decisions were recorded.

Genomic Prostate Score risk stratification was performed in 134 men. According to the NCCN Guidelines® 31 of the 134 men (23.1%) were at very low risk, 45 (33.6%) were at low risk and 58 (43.3%) were at intermediate risk. After adding the score the risk group changed in 32 of 134 patients (23.9%). The risk group did not change in the 31 men at very low risk. However, in the low risk group the risk changed in 19 of the 45 men (42.2%), including in 15 to very low and in 4 to intermediate risk. Also, in the intermediate risk group the risk changed in 13 of the 58 men (22.4%), including in 12 to low and in 1 to high risk. Nine of the 15 men (60%) in whom risk changed from low to very low elected active surveillance. Nine of the 12 patients (75%) at intermediate risk in whom risk changed to low risk elected active surveillance, 2 (16.7%) elected definitive therapy and in 1 (8.3%) the choice was unknown. Of the 45 men at intermediate risk in whom risk was unchanged 28 (62.2%) elected definitive therapy, 12 (26.0%) elected active surveillance and in 5 (11.1%) the choice was unknown. Of the 4 men upgraded from low to intermediate risk after adding the genomic prostate score 2 elected definitive therapy and 2 chose active surveillance.

The Genomic Prostate Score has limited clinical usefulness in patients at very low risk since the NCCN risk group did not change. While it may be more useful in men at low and intermediate risk, in 32 (31%) of whom the risk group was reclassified, clinical management decisions did not always appear to reflect these changes.

The Journal of urology. 2019 Feb 12 [Epub ahead of print]

Christopher Gaffney, Ron Golan, Miguel D Cantu, Theresa Scognamiglio, Hiral McCarthy, Juan Miguel Mosquera, Timothy D McClure, Christopher E Barbieri, Brian D Robinson, Francesca Khani

Departments of Urology , New York , New York., Pathology and Laboratory Medicine , New York , New York., Weill Cornell Medicine , New York , New York.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe